Literatur
- 1
Agelink M W, Majewski T, Wurthmann C. et al .
Effects of newer atypical
antipsychotics on autonomic neurocardiac function: a comparison
between amisulpride, olanzapine, sertindole, and clozapine.
J Clin
Psychopharmacol.
2001;
21
8-13
- 2
Allison D B, Mentore J L, Heo M. et al .
Antipsychotic-induced weight gain: a comprehensive
research synthesis.
Am J Psychiatry.
1999;
156
1686-96
- 3
Arzneimittelkommission der
deutschen Ärzteschaft .
Blutbildveränderungen
unter dem neueren atypischen Neuroleptikum Olanzapin.
Dtsch
Aerztbl.
2001;
3
130
- 4 Arznei-Telegramm. 2000 31: 31-2
- 5 Arznei-Telegramm. 2004 35: 2-4
- 6 Arznei-Telegramm. 2005 36: 51-2
- 7
Beasley Jr C M, Sanger T, Satterlee W. et al .
Olanzapine versus placebo: results
of a double-blind, fixed-dose olanzapine trial.
Psychopharmacology
(Berl).
1996;
124
159-67
- 8
Berk M, Ichim L, Brook S.
Olanzapine
compared to lithium in mania: a double-blind randomized controlled
trial.
Int Clin Psychopharmacol.
1999;
14
339-43
- 9
Bryden K E, Kopala L C.
Body mass index
increase of 58 % associated with olanzapine.
Am J Psychiatry.
1999;
156
1835-6
- 10
Callaghan J T, Bergstrom R F, Ptak L R. et al .
Olanzapine. Pharmacokinetic
and pharmacodynamic profile.
Clin Pharmacokinet.
1999;
37
177-93
- 11
Consensus development conference
on antipsychotic and obesity and diabetes.
Diabetes Care.
2004;
27
596-601
- 12 Fachinformation. Zyprexa, Olanzapin. Stand 2006
- 13
Henderson D C, Cagliero E, Copeland P M. et al .
Glucose metabolism in patients with schizophrenia
treated with atypical antipsychotic agents: a frequently sampled
intravenous glucose tolerance test and minimal model analysis.
Arch Gen Psychiatry.
2005;
62
19-28
- 14 Jayaram M B, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane
Database Syst Rev 2006 CD005237
- 15
Kinon B J, Lieberman J A.
Mechanisms
of action of atypical antipsychotic drugs: a critical analysis.
Psychopharmacology (Berl).
1996;
124
2-34
- 16
Lieberman J A, Stroup T S, McEvoy J P. et al .
Effectiveness of antipsychotic
drugs in patients with chronic schizophrenia.
N Engl J
Med.
2005;
353
1209-23
- 17
Lindenmayer J P, Khan A, Iskander A. et al .
A randomized controlled trial of olanzapine
versus haloperidol in the treatment of primary negative symptoms
and neurocognitive deficits in schizophrenia.
J Clin Psychiatry.
2007;
68
368-79
- 18
Rabinowitz J, Lichtenberg P, Kaplan Z. et al .
Rehospitalization rates of chronically
ill schizophrenic patients discharged on a regimen of risperidone,
olanzapine, or conventional antipsychotics.
Am J Psychiatry.
2001;
158
266-9
- 19
Sacchetti E, Valsecchi P, Parrinello G.
A randomized, flexible-dose, quasi-naturalistic comparison of
quetiapine, risperidone, and olanzapine in the short-term treatment
of schizophrenia: the QUERISOLA trial.
Schizophr Res.
2008;
98
55-65
- 20 Schwabe U PD. Arzneiverordnungs-Report 2006. Heidelberg; Springer-Verlag 2007
- 21
Stroup T S, McEvoy J P, Swartz M S. et al .
The National Institute of
Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
project: schizophrenia trial design and protocol development.
Schizophr Bull.
2003;
29
15-31
- 22
Tandon R.
Safety and tolerability: how do newer generation „atypical” antipsychotics
compare?.
Psychiatr Q.
2002;
73
297-311
- 23
Tohen M, Greil W, Calabrese J R. et al .
Olanzapine versus lithium in the maintenance
treatment of bipolar disorder: a 12-month, randomized, double-blind,
controlled clinical trial.
Am J Psychiatry.
2005;
162
1281-90
- 24
Tohen M, Sanger T M, McElroy S L. et al .
Olanzapine versus placebo
in the treatment of acute mania. Olanzapine HGEH Study Group.
Am J Psychiatry.
1999;
156
702-9
- 25
Tollefson G D, Beasley Jr C M, Tamura R N. et al .
Blind, controlled,
long-term study of the comparative incidence of treatment-emergent
tardive dyskinesia with olanzapine or haloperidol.
Am
J Psychiatry.
1997;
154
1248-54
- 26
Tran P V, Dellva M A, Tollefson G D. et al .
Oral olanzapine versus oral haloperidol
in the maintenance treatment of schizophrenia and related psychoses.
Br J Psychiatry.
1998;
172
499-505
- 27
Tran P V, Hamilton S H, Kuntz A J. et al .
Double-blind comparison
of olanzapine versus risperidone in the treatment of schizophrenia
and other psychotic disorders.
J Clin Psychopharmacol.
1997;
17
407-18
Katrin Wittköpper
Institut für Experimentelle und Klinische
Pharmakologie und Toxikologie, Universitätsklinikum
Hamburg-Eppendorf, Hamburg
Martinistraße 52
20246 Hamburg
Telefon: 040 42803/2180
Fax: 040 42803/4876
